KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Change in Account Payables: 2010-2025

Historic Change in Account Payables for Pacira BioSciences (PCRX) over the last 9 years, with Sep 2025 value amounting to -$12.0 million.

  • Pacira BioSciences' Change in Account Payables fell 1985.87% to -$12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.0 million, marking a year-over-year decrease of 228.11%. This contributed to the annual value of $3.1 million for FY2024, which is 236.68% up from last year.
  • According to the latest figures from Q3 2025, Pacira BioSciences' Change in Account Payables is -$12.0 million, which was down 274.61% from $6.9 million recorded in Q2 2025.
  • Pacira BioSciences' 5-year Change in Account Payables high stood at $9.7 million for Q2 2024, and its period low was -$12.0 million during Q3 2025.
  • Its 3-year average for Change in Account Payables is $121,000, with a median of $637,000 in 2024.
  • Per our database at Business Quant, Pacira BioSciences' Change in Account Payables spiked by 932.94% in 2023 and then tumbled by 1,985.87% in 2025.
  • Pacira BioSciences' Change in Account Payables (Quarterly) stood at -$9.4 million in 2021, then soared by 116.86% to $1.6 million in 2022, then crashed by 167.38% to -$1.1 million in 2023, then skyrocketed by 69.68% to -$325,000 in 2024, then slumped by 1,985.87% to -$12.0 million in 2025.
  • Its last three reported values are -$12.0 million in Q3 2025, $6.9 million for Q2 2025, and $2.5 million during Q1 2025.